Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs Cleerly LABS

Acumen HPI is deeply integrated into the Edwards Lifesciences HemoSphere Advanced Monitoring Platform, providing continuous, real-time data and alerts directly at the point of care. This seamless integration into existing critical care workflows, with immediate HPI scores and smart alerts, makes it highly usable for proactive decision-making in fast-paced environments. Cleerly LABS, while offering a user-friendly web-based interface and integration with radiology systems, is a diagnostic tool with a processing time, not designed for real-time bedside intervention.

Both tools demonstrate significant clinical value backed by studies and FDA clearance. Acumen HPI has shown a 57% reduction in the duration of intraoperative hypotension and superior predictive abilities, directly impacting acute patient outcomes and reducing associated risks like myocardial injury and AKI. Cleerly LABS provides comprehensive, quantitative insights into coronary artery disease from CCTA, which has been shown to reduce heart attacks by 41% and aids in personalized, long-term heart disease management. Their contributions are distinct but equally critical to patient care.

Cleerly LABS offers transparent pricing information, including a retail price, a discounted rate, and details on potential insurance coverage and out-of-pocket costs, allowing for a clear assessment of its value. In contrast, Acumen HPI's pricing is not publicly disclosed, requiring direct contact for information, which makes it challenging for potential customers to evaluate its cost-effectiveness upfront.

Cleerly LABS exhibits stronger enterprise readiness with its cloud-based (AWS) architecture, offering high scalability and accessibility, and its Cleerly Proxy solution for seamless integration with diverse PACS, RIS, and EHR systems. The Cleerly Proxy is described as a 'turnkey solution' that can be installed quickly, enhancing its adaptability across various hospital IT environments. While Acumen HPI is FDA cleared and HIPAA compliant, its deployment is tied to a specific hardware platform, potentially limiting its flexibility for broader enterprise adoption.

Both tools represent significant innovation in their respective fields. Acumen HPI is a 'first-of-its-kind' technology that uses machine learning for real-time prediction of hypotensive events up to 15 minutes in advance, providing proactive insights into hemodynamic instability. Cleerly LABS innovates by offering comprehensive, AI-powered quantitative analysis of CCTA to detect, quantify, and characterize atherosclerosis and stenosis, aiming to create a new standard of care for heart disease management and prevention. Their distinct applications of AI are equally groundbreaking.

Edwards Lifesciences, as a large and established medical device company, provides robust support, including 24/7 technical assistance and a comprehensive 'Edwards clinical education' program with a broad range of resources and tools. While Cleerly offers client support during business hours and dedicated implementation specialists for its proxy solution, the extensive, continuous educational commitment and round-the-clock technical support from Edwards Lifesciences give Tool A an advantage in overall support and documentation.